WILMINGTON, Del. – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has initiated the process for U.S. Food & Drug Administration (FDA) approval of its drug candidate NRX-100 (ketamine) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback